Mark Davies is BenevolentAI’s Senior Vice President of Informatics and Data and is responsible for acquiring and processing the vast amounts of biomedical data used to build the BenevolentAI Knowledge Graph. Throughout his career Mark has worked at the interface of technology and drug discovery and has focused on building Platforms that help maximise the impact biomedical, chemical and patient-level big data can have on the drug discovery process. His team at BenevolentAI is continuing to innovate in this research space.
Mark has a background in molecular genetics, bioinformatics and computer science and has over 20 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the biotechnology company Inpharmatica, where he worked on mining the output of the Human Genome Projects and building chemogenomic systems used by Big Pharma. Mark then moved to the European Bioinformatics Institute (EMBL-EBI) and helped lead and contribute to a number of large public biomedical data initiatives, which included ChEMBL, SureChEMBL and OpenPHACTS.